Skip to main content
NCBI home page
Gut logoLink to Gut
. 1995 Dec;37(6):811–818. doi: 10.1136/gut.37.6.811

Identifying patients with a high risk of relapse in quiescent Crohn's disease. The GETAID Group. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.

T Sahmoud 1, G Hoctin-Boes 1, R Modigliani 1, A Bitoun 1, J F Colombel 1, J C Soule 1, C Florent 1, J P Gendre 1, E Lerebours 1, R Sylvester 1
PMCID: PMC1382944  PMID: 8537053

Abstract

No reliable identification of quiescent Crohn's disease (CD) patients with a high risk of relapse is available. The aim of this study was to develop a prognostic index to identify those patients. Untreated adult patients with quiescent disease (not induced by surgery) included in three phase III clinical trials were analysed retrospectively with respect to time to relapse. Nineteen factors related to biology, disease history, and topography were investigated. A relapse was defined as either a CD Activity Index (CDAI) > or = 200, a CDAI > or = 150 but over the baseline value by more than 100, or acute complications requiring surgery. The inclusion criteria were fulfilled by 178 patients. The median follow up was 23 months. The Cox model retained the following bad prognostic factors: age < or = 25 years, interval since first symptoms > 5 years, interval since previous relapse < or = 6 months, and colonic involvement (p < 0.001). Bootstrapping confirmed the variable selection. Patients were classified into three groups with an increasing risk of relapse (p < 0.001). The worst risk group was composed of patients presenting at least three of the four bad prognostic factors. These results make possible the design of clinical trials in quiescent CD patients with a high risk of relapse.

Full text

PDF
811

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Altman D. G., De Stavola B. L. Practical problems in fitting a proportional hazards model to data with updated measurements of the covariates. Stat Med. 1994 Feb 28;13(4):301–341. doi: 10.1002/sim.4780130402. [DOI] [PubMed] [Google Scholar]
  2. Basilisco G., Campanini M., Cesana B., Ranzi T., Bianchi P. Risk factors for first operation in Crohn's disease. Am J Gastroenterol. 1989 Jul;84(7):749–752. [PubMed] [Google Scholar]
  3. Beeken W. L., Sessions J. T., Jr, Bozymski E. M. Correlations between clinical, blood leukocyte, and skin test data in the National Cooperative Crohn's Disease Study. Gastroenterology. 1979 Oct;77(4 Pt 2):921–924. [PubMed] [Google Scholar]
  4. Bernades P., Hecketsweiler P., Benozio M., Descos L., Geffroy Y., Hemet J., Loygue J., Modigliani R., Potet F., Weill J. P. Proposition d'un système de critères pour le diagnostic des entérocolites inflammatoires cryptogénétiques (maladie de Crohn et rectocolite hémorragique). Une étude coopérative du g. r. e. c. Gastroenterol Clin Biol. 1978 Dec;2(12):1047–1054. [PubMed] [Google Scholar]
  5. Best W. R., Becktel J. M., Singleton J. W. Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology. 1979 Oct;77(4 Pt 2):843–846. [PubMed] [Google Scholar]
  6. Brignola C., Campieri M., Bazzocchi G., Farruggia P., Tragnone A., Lanfranchi G. A. A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease. Gastroenterology. 1986 Dec;91(6):1490–1494. doi: 10.1016/0016-5085(86)90206-4. [DOI] [PubMed] [Google Scholar]
  7. Gendre J. P., Mary J. Y., Florent C., Modigliani R., Colombel J. F., Soulé J. C., Galmiche J. P., Lerebours E., Descos L., Viteau J. M. Oral mesalamine (Pentasa) as maintenance treatment in Crohn's disease: a multicenter placebo-controlled study. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID) Gastroenterology. 1993 Feb;104(2):435–439. doi: 10.1016/0016-5085(93)90411-5. [DOI] [PubMed] [Google Scholar]
  8. Goldberg H. I., Caruthers S. B., Jr, Nelson J. A., Singleton J. W. Radiographic findings of the National Cooperative Crohn's Disease Study. Gastroenterology. 1979 Oct;77(4 Pt 2):925–937. [PubMed] [Google Scholar]
  9. Landi B., Anh T. N., Cortot A., Soule J. C., Rene E., Gendre J. P., Bories P., See A., Metman E. H., Florent C. Endoscopic monitoring of Crohn's disease treatment: a prospective, randomized clinical trial. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gastroenterology. 1992 May;102(5):1647–1653. doi: 10.1016/0016-5085(92)91725-j. [DOI] [PubMed] [Google Scholar]
  10. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966 Mar;50(3):163–170. [PubMed] [Google Scholar]
  11. Mary J. Y., Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut. 1989 Jul;30(7):983–989. doi: 10.1136/gut.30.7.983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Mekhjian H. S., Switz D. M., Melnyk C. S., Rankin G. B., Brooks R. K. Clinical features and natural history of Crohn's disease. Gastroenterology. 1979 Oct;77(4 Pt 2):898–906. [PubMed] [Google Scholar]
  13. Modigliani R., Pieddeloup C., Hecketsweiler P., Descos L., Lerebours E., Vernisse B., Costil V., Bitoun A., Lacroute J. M., Maire P. Effet du levamisole sur la prévention des poussées évolutives de la maladie de Crohn quiescente: un essai prospectif multicentrique contrôlé sur 155 malades. Gastroenterol Clin Biol. 1983 Aug-Sep;7(8-9):683–692. [PubMed] [Google Scholar]
  14. Mörl M., Zöberlein H. G., Classen M. Morbus Crohn. Verlauf und Prognose bei 169 Kranken. Dtsch Med Wochenschr. 1978 Aug 25;103(34):1325–1329. doi: 10.1055/s-0028-1129256. [DOI] [PubMed] [Google Scholar]
  15. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Prantera C., Pallone F., Brunetti G., Cottone M., Miglioli M. Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease. The Italian IBD Study Group. Gastroenterology. 1992 Aug;103(2):363–368. doi: 10.1016/0016-5085(92)90822-g. [DOI] [PubMed] [Google Scholar]
  17. Sachar D. B. Predicting relapses of Crohn's disease. Clouds in the crystal ball. Dig Dis Sci. 1987 Feb;32(2):206–208. doi: 10.1007/BF01297109. [DOI] [PubMed] [Google Scholar]
  18. Steinhardt H. J., Loeschke K., Kasper H., Holtermüller K. H., Schäfer H. European Cooperative Crohn's Disease Study (ECCDS): clinical features and natural history. Digestion. 1985;31(2-3):97–108. doi: 10.1159/000199186. [DOI] [PubMed] [Google Scholar]
  19. Weterman I. T., Biemond I., Peña A. S. Mortality and causes of death in Crohn's disease. Review of 50 years' experience in Leiden University Hospital. Gut. 1990 Dec;31(12):1387–1390. doi: 10.1136/gut.31.12.1387. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Winship D. H., Summers R. W., Singleton J. W., Best W. R., Becktel J. M., Lenk L. F., Kern F., Jr National Cooperative Crohn's Disease Study: study design and conduct of the study. Gastroenterology. 1979 Oct;77(4 Pt 2):829–842. [PubMed] [Google Scholar]
  21. Wright J. P., Young G. O., Tigler-Wybrandi N. Predictors of acute relapse of Crohn's disease. A laboratory and clinical study. Dig Dis Sci. 1987 Feb;32(2):164–170. doi: 10.1007/BF01297104. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES